Phase Ib-II study of ramucirumab combined with nab-paclitaxel and Gemcitabine as first-line treatment in patients with advanced pancreatic adenocarcinoma (RACING).
INTRODUCTION The aim of the present clinical trial was to evaluate the efficacy and toxicity of ramucirumab in combination with nab-paclitaxel and gemcitabine as first-line treatment in locally advanced or metastatic pancreatic adenocarcinoma. METHODS This was a prospective, single-arm, phase Ib-II trial. In phase Ib...